IP Library Patent Application 18179035
Patent Application
App. No. 18/179,035

COMPOSITIONS AND METHODS FOR MAKING (R)-RETICULINE AND PRECURSORS THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/179,035
Abstract

Methods that may be used for the manufacture of the chemical compound (R)-Reticuline and synthesis precursors thereof. Compositions useful for the synthesis (R)-Reticuline and synthesis precursors are also provided.

Claims (30)

1 - 84 . (canceled)

85 . A recombinant nucleic acid comprising a nucleic acid sequence at least 70% identical to one or more of the nucleic acid sequences selected from the group consisting of:

(i) SEQ ID NO: 116-218, SEQ ID NO: 324, and SEQ ID NO: 337;

(ii) a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 219-321, SEQ ID NO: 325, and SEQ ID NO: 338;

(iii) SEQ ID NO: 1-58, SEQ ID NO: 326, SEQ ID NO: 328, and SEQ ID NO: 339;

(iv) a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 59-115, SEQ ID NO: 327; SEQ ID NO: 329, SEQ ID NO: 330, and SEQ ID NO: 340;

(v) SEQ ID NO: 322; and

(vi) a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 323.

86 . The recombinant nucleic acid according to claim 85 , wherein the nucleic acid is a complementary DNA (cDNA).

87 . A chimeric nucleic acid sequence comprising:

(a) a first nucleic acid sequence encoding a CYP450 polypeptide; and

(b) a second nucleic acid sequence encoding an AKR polypeptide; and

(c) one or more nucleic acid sequences capable of controlling expression in a host cell.

88 . The chimeric nucleic acid sequence according to claim 87 , wherein the first nucleic acid sequence comprises a nucleic acid sequence at least 70% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 116-218, SEQ ID NO: 324, and SEQ ID NO: 337.

89 . The chimeric nucleic acid sequence according to claim 87 , wherein the second nucleic acid sequence comprises a nucleic acid sequence at least 70% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-58, SEQ ID NO: 326, SEQ ID NO: 328, and SEQ ID: NO: 339.

90 . The chimeric nucleic acid sequence according to claim 87 , wherein (i) the first nucleic acid sequence comprises a nucleic acid sequence at least 70% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 116-218, SEQ ID NO: 324, and SEQ ID NO: 337, and (ii) the second nucleic acid sequence comprises a nucleic acid sequence at least 70% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-58, SEQ ID NO: 326, SEQ ID NO: 328, and SEQ ID: NO: 339.

91 . The chimeric nucleic acid sequence according to claim 87 , wherein the nucleic acid sequence capable of controlling expression comprises a promoter, a transcriptional terminator, a transcriptional enhancer, or combinations thereof.

92 . A recombinant expression vector comprising as operably linked components:

(a) a nucleic acid sequence capable of controlling expression in a host cell; and

(b) a nucleic acid sequence encoding CYP450 and AKR;

wherein the expression vector is suitable for expression in a host cell.

93 . The recombinant expression vector according to claim 92 , wherein the nucleic acid sequence encoding CYP450 comprises a nucleic acid sequence at least 70% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 116-218, SEQ ID NO: 324, and SEQ ID NO: 337.

94 . The recombinant expression according to claim 92 , wherein the nucleic acid sequence encoding AKR comprises a nucleic acid sequence at least 70% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-58, SEQ ID NO: 326, SEQ ID NO: 328, and SEQ ID NO: 339.

95 . The recombinant expression vector of claim 92 , wherein the nucleic acid sequence encoding CYP450 and AKR comprises at least 70% identical to the nucleic acid sequence of SEQ ID NO: 322.

96 . The recombinant expression vector of claim 92 , wherein the nucleic acid sequence capable of controlling expression in a host cell comprises a promoter, a transcriptional terminator, a transcriptional enhancer, or combinations thereof.

97 . The recombinant expression vector of claim 92 , further comprising one or more nucleic acid sequences encoding marker genes, one or more origins of replication, genetic elements required for the integration of the vector or a portion thereof into the host cell's genome, or combinations thereof.

98 . A host cell comprising a nucleic acid sequence according to claim 1 .

99 . The host cell of claim 98 , wherein the host cell is a non-plant cell.

100 . The host cell of claim 99 , wherein the host cell is Escherichia coli.

101 . The host cell of claim 99 , wherein the host cell is a yeast cell.

Assignments (6)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2023
From: FACCHINI, PETER J.; FARROW, SCOTT; BEAUDOIN, GUILLAUME
To: UTI LIMITED PARTNERSHIP
Reel/Frame 062906/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2023
From: UTI LIMITED PARTNERSHIP
To: EPIMERON INC.
Reel/Frame 062906/0944 →
MERGER Recorded Mar 7, 2023
From: WILLOW BIOSCIENCES, INC.; EPIMERON INCORPORATED; VINDOLON INCORPORATED; SERTURNER CORPORATION
To: WILLOW BIOSCIENCES, INC.
Reel/Frame 062906/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2023
From: WILLOW BIOSCIENCES, INC.
To: ELESZTO GENETIKA INC.
Reel/Frame 062906/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2023
From: ELESZTO GENETIKA, INC.
To: ANTHEIA, INC.
Reel/Frame 062906/0982 →